Medication Management of Co-Occurring Opioid Use Disorder in Mental Health Settings: A Guide for Practitioners

2021 ◽  
Keyword(s):  
Mental Health ◽  
Medication Management ◽  
Opioid Use Disorder ◽  
Opioid Use ◽  
Mental Health Settings

scholarly journals Substance Use and Mental Health in Emerging Adult Vs Older Adult Men and Women With Opioid Use Disorder

2020 ◽  
Vol 29 (6) ◽  
pp. 536-542 ◽  
Author(s):  
Celestina Barbosa‐Leiker ◽  
Aimee N.C. Campbell ◽  
Martina Pavlicova ◽  
Jennifer Scodes ◽  
A. Kathleen Burlew ◽  
...  
Keyword(s):  
Mental Health ◽  
Substance Use ◽  
Older Adult ◽  
Emerging Adult ◽  
Opioid Use Disorder ◽  
Opioid Use ◽  
Men And Women ◽  
Adult Men

Latent Class Analysis of DSM-5 Criteria for Opioid Use Disorders: Results from the Iranian National Survey on Mental Health

2015 ◽  
Vol 21 (3) ◽  
pp. 144-152 ◽  
Author(s):  
Mohammad Javad Tarrahi ◽  
Afarin Rahimi-Movaghar ◽  
Hojjat Zeraati ◽  
Seyed Abbas Motevalian ◽  
Masoumeh Amin-Esmaeili ◽  
...  
Keyword(s):  
Mental Health ◽  
Latent Class ◽  
Composite International Diagnostic Interview ◽  
Opioid Use Disorder ◽  
Diagnostic Interview ◽  
Opioid Use ◽  
Dsm 5 ◽  
Legal Problems ◽  
Dsm Iv ◽  
Opioid Users

Background: Assessments of DSM-IV and DSM-5 criteria with sample populations of opioid users are limited. This study aimed to determine the number of latent classes in opioid users and assessment of the proposed revisions to the DSM-5 opioid use disorder (OUD) criteria. Methods: Data came from the 2011 Iranian National Mental Health Survey (IranMHS) on 7,886 participants aged 15-64 years living in Iran. We used the Composite International Diagnostic Interview (CIDI) version 2.1 in all respondents who indicated using opioids at least 5 times in the previous 12 months (n = 236). Results: A three-class model provided the best fit of all the models tested. Classes showed a spectrum of severity that was compatible with the DSM-5 classification. ‘Legal problems' and ‘desire to cut down' showed poor discrimination between classes. The weighted prevalence of OUD using DSM-5 was 20.7% higher than with DSM-IV. Conclusions: Results support the grouping based on severity of symptoms, combining abuse and dependence into a single diagnosis, omitting legal problems, and addition of craving as a new criterion.

Empowering Psychiatric Mental Health Nurse Practitioners to Expand Treatment Opportunities for Veterans With Opioid Use Disorder

2020 ◽  
Vol 31 (4) ◽  
pp. 261-268
Author(s):  
Jennifer Jones ◽  
Matthew Tierney ◽  
Gabrielle Jacobs ◽  
Shao-Yun Chien ◽  
Sandra Mallisham
Keyword(s):  
Mental Health ◽  
Nurse Practitioners ◽  
Opioid Use Disorder ◽  
Opioid Use ◽  
Mental Health Nurse ◽  
Health Nurse

scholarly journals Impact of opioid agonists on mental health in substitution treatment for opioid use disorder: A systematic review and Bayesian network meta-analysis of randomized clinical trials

2020 ◽  
Author(s):  
Ehsan Moazen-Zadeh ◽  
Kimia Ziafat ◽  
Kiana Yazdani ◽  
Mostafa Mamdouh ◽  
James Wong ◽  
...  
Keyword(s):  
Mental Health ◽  
Systematic Review ◽  
Clinical Trials ◽  
Randomized Clinical Trials ◽  
Meta Analysis ◽  
Opioid Use Disorder ◽  
Substitution Treatment ◽  
Opioid Use ◽  
Psychosocial Services ◽  
Opioid Medications

AbstractObjectiveThere is a dearth of high-quality systematic evidence on the impact of opioid substitution medications on mental health. We compared mental health outcomes between opioid medications and placebo/waitlist, and between different opioids.MethodsThis systematic review and meta-analysis of randomized clinical trials (RCTs) was pre-registered at PROSPERO (CRD42018109375). Embase, MEDLINE, PsychInfo, CINAHL Complete, and Web of Science Core Collection were searched from inception to May 2020. RCTs were included if they compared opioid agonists with each other or with a placebo/waitlist in substitution treatment of patients with opioid use disorder, and reported at least one mental health outcome on a span of more than 1-month post baseline. Studies with psychiatric care, adjunct psychotropic medications, or unbalanced psychosocial services were excluded. Primary outcomes were comparison of depressive symptoms and overall mental health between opioids and placebo/waitlist. Random effects model was used for all the meta-analysis.ResultsNineteen studies were included in the narrative synthesis and 15 in the quantitative synthesis. Hydromorphone, diacetylmorphine (DAM), methadone, slow-release oral morphine, buprenorphine, and placebo/waitlist were among the included interventions. Based on network meta-analysis for primary outcomes, buprenorphine (SMD (CI95%)= −0.61 (−1.20, −0.11)), DAM (−1.40 (−2.70, −0.23)), and methadone (−1.20 (−2.30, −0.11)) were superior to waitlist/placebo on overall mental health. Further direct pairwise meta-analysis indicated that overall mental health improved more in DAM compared to methadone (−0.23 (−0.34, −0.13)).ConclusionsIt appears that opioid medications improve mental health independent of psychosocial services. Potential contribution of other factors needs to be further investigated.

scholarly journals Integrating Psychological Services Into Community-Based Clinics

2021 ◽  
Vol 5 (Supplement_1) ◽  
pp. 527-527
Author(s):  
Lindsey Jacobs
Keyword(s):  
Mental Health ◽  
Health Services ◽  
Behavioral Health ◽  
Behavioral Health Care ◽  
Opioid Use Disorder ◽  
Current Status ◽  
Mental Health Stigma ◽  
Behavioral Health Services ◽  
Opioid Use ◽  
Integrated Behavioral Health

Abstract In Alabama, where mental health stigma is a critical barrier to care, integrated behavioral health services are vital to address the mental health needs that underlie substance use disorder (SUD) and opioid use disorder (OUD). Since October 2019, our team has developed partnerships with one rural and two peri-urban primary care clinics to offer behavioral health services with an emphasis on SUD/OUD prevention, screening, and treatment. The patient populations receiving services at these three facilities are under-resourced with multiple disadvantages placing them at risk for morbidity, mortality, SUD/OUD, and poor behavioral and mental health outcomes. Behavioral health services have been delivered primarily via telehealth due to the COVID-19 pandemic. This presentation will describe the process, current status, and future goals for implementing integrated behavioral health care, with a focus on identifying the barriers and facilitators during the COVID-19 pandemic era.

Mental Health Conditions and Substance Use Disorders Among Youth Subsequently Diagnosed With Opioid Use Disorder or Opioid Poisoning

2021 ◽  
Vol Publish Ahead of Print ◽  
Author(s):  
Edeanya Agbese ◽  
Bradley D. Stein ◽  
Benjamin G. Druss ◽  
Andrew W. Dick ◽  
Rosalie L. Pacula ◽  
...  
Keyword(s):  
Mental Health ◽  
Substance Use ◽  
Substance Use Disorders ◽  
Opioid Use Disorder ◽  
Health Conditions ◽  
Opioid Use ◽  
Mental Health Conditions

scholarly journals Modeling SARS-CoV-2 infection in individuals with opioid use disorder with brain organoids

2021 ◽  
Vol 12 ◽  
pp. 204173142098529
Author(s):  
Moshe J Willner ◽  
Yang Xiao ◽  
Hye Sung Kim ◽  
Xuejing Chen ◽  
Bin Xu ◽  
...  
Keyword(s):  
Mental Health ◽  
Opioid Use Disorder ◽  
Financial Instability ◽  
Potential Utility ◽  
Health Issues ◽  
Opioid Use ◽  
Neurological Sequelae ◽  
Mental Health Issues ◽  
Brain Organoid

The COVID-19 pandemic has aggravated a preexisting epidemic: the opioid crisis. Much literature has shown that the circumstances imposed by COVID-19, such as social distancing regulations, medical and financial instability, and increased mental health issues, have been detrimental to those with opioid use disorder (OUD). In addition, unexpected neurological sequelae in COVID-19 patients suggest that COVID-19 compromises neuroimmunity, induces hypoxia, and causes respiratory depression, provoking similar effects as those caused by opioid exposure. Combined conditions of COVID-19 and OUD could lead to exacerbated complications. With limited human in vivo options to study these complications, we suggest that iPSC-derived brain organoid models may serve as a useful platform to investigate the physiological connection between COVID-19 and OUD. This mini-review highlights the advances of brain organoids in other neuropsychiatric and infectious diseases and suggests their potential utility for investigating OUD and COVID-19, respectively.

Sign in / Sign up

Export Citation Format

Share Document